Lilly shares climb as next-generation obesity drug data cements market lead

Eli Lilly (LLY) shares rose 4% after the drugmaker presented compelling data for retatrutide, its next-generation obesity treatment, fueling expectations among analysts and investors that the company will extend its dominance of the booming weight-loss market.

The Indianapolis-based group unveiled full results from two retatrutide trials at the American Diabetes Association meeting in New Orleans — one in treatment-naive type 2 diabetes patients and another in patients with obesity.

Investors were most encouraged by the performance of the lower 4 mg dose, which delivered roughly 19% weight loss, comparable to the highest dose of Zepbound, Lilly's current blockbuster therapy. Tolerability was broadly in line, with similar rates of treatment discontinuation and relatively low levels of vomiting, though side effects increased at higher doses.

"The 4mg dose efficacy data for retatrutide are compelling enough that first-line positioning cannot be dismissed," Citi analysts said in a note, adding that the data position the drug as "the next step for patients who have exhausted Lilly's tirzepatide efficacy."

Drugmakers in the obesity space are increasingly competing on tolerability, seeking to balance strong efficacy with fewer side effects and simpler dosing in order to drive wider adoption.

Lilly shares have gained 9% so far this year, building on a huge rally in 2025. By contrast, shares in Novo Nordisk (NVO), its closest rival, have fallen roughly 17% year to date. Some analysts flagged that retatrutide could emerge as a potent new competitor for Novo from next year.

"LLY has the pieces in place to further raise the standard of care in the obesity space, and we see the company if anything further extending its leadership position in the $200bn+ incretin/obesity market longer term," said J.P. Morgan analyst Chris Schott.

Lilly also presented additional data on other pipeline candidates, including its approved weight-loss pill and eloralintide, an experimental injectable. RBC Capital Markets analyst Trung Huynh said the depth of Lilly's obesity portfolio "highlighted its leadership growing rather than a narrowing gap with competitors."